The predictive factors and predictive models as well as nomograms for LNI in patients with prostate cancer were investigated in one study, whose results demonstrated that some clinical indicators, including serum prostate-specific antigen (PSA) concentration, clinical stage, and biopsy Gleason score may estimate the risk of LN metastasis.12 However, these tools which may be utilized for the purpose of patient selection for PLND usually only provide stratification of a patient’s risk of LNI, with the decision on who should undergo PLND left to the surgeon’s judgment.13 The gene discussed is KLK3; the disease is prostate carcinoma.